High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma

J. R. Mills, D. R. Barnidge, Angela Dispenzieri, D. L. Murray

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

We assessed the ability of a mass spectrometry-based technique, called monoclonal immunoglobulin rapid accurate mass measurement (miRAMM), to extend the analytical range of M-protein detection in serum samples obtained from myeloma patients in stringent complete response (sCR) post-autologous stem cell transplant (ASCT). To aid the M-protein detection post ASCT, the accurate molecular mass of the M-protein light chain at diagnosis was determined in all patients (N=30) and used to positively identify clones in the sCR serum. Day 100 post-ASCT, sCR samples had miRAMM identifiable M-proteins in 81% of patients. Patients who had achieved only a partial remission (PR) pre-ASCT and those with IgG isotypes serum samples had the highest rate of M-protein detection by miRAMM. miRAMM positivity at single time points (day 100, 6 months or 12 months) did not correlate with progression-free survival (PFS). In contrast, sCR patients who did not decrease their miRAMM M-protein intensities in serial measurements had shorter PFS than those whose miRAMM intensities decreased (median 17.9 months vs 51.6 months; P<0.0017). miRAMM M-protein is a more sensitive blood-based test than traditional M-protein tests and could cost effectively aid in serially monitoring complete remission for continue response or biochemical relapse.

Original languageEnglish (US)
Article numbere590
JournalBlood Cancer Journal
Volume7
Issue number8
DOIs
StatePublished - Aug 25 2017

Fingerprint

Multiple Myeloma
Immunoglobulins
Proteins
Stem Cells
Transplants
Disease-Free Survival
Serum
Hematologic Tests
Mass Spectrometry
Clone Cells
Immunoglobulin G
Light
Costs and Cost Analysis
Recurrence

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma. / Mills, J. R.; Barnidge, D. R.; Dispenzieri, Angela; Murray, D. L.

In: Blood Cancer Journal, Vol. 7, No. 8, e590, 25.08.2017.

Research output: Contribution to journalArticle

@article{9f7cf50b6c9f4551bee98e887a98210c,
title = "High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma",
abstract = "We assessed the ability of a mass spectrometry-based technique, called monoclonal immunoglobulin rapid accurate mass measurement (miRAMM), to extend the analytical range of M-protein detection in serum samples obtained from myeloma patients in stringent complete response (sCR) post-autologous stem cell transplant (ASCT). To aid the M-protein detection post ASCT, the accurate molecular mass of the M-protein light chain at diagnosis was determined in all patients (N=30) and used to positively identify clones in the sCR serum. Day 100 post-ASCT, sCR samples had miRAMM identifiable M-proteins in 81{\%} of patients. Patients who had achieved only a partial remission (PR) pre-ASCT and those with IgG isotypes serum samples had the highest rate of M-protein detection by miRAMM. miRAMM positivity at single time points (day 100, 6 months or 12 months) did not correlate with progression-free survival (PFS). In contrast, sCR patients who did not decrease their miRAMM M-protein intensities in serial measurements had shorter PFS than those whose miRAMM intensities decreased (median 17.9 months vs 51.6 months; P<0.0017). miRAMM M-protein is a more sensitive blood-based test than traditional M-protein tests and could cost effectively aid in serially monitoring complete remission for continue response or biochemical relapse.",
author = "Mills, {J. R.} and Barnidge, {D. R.} and Angela Dispenzieri and Murray, {D. L.}",
year = "2017",
month = "8",
day = "25",
doi = "10.1038/bcj.2017.75",
language = "English (US)",
volume = "7",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma

AU - Mills, J. R.

AU - Barnidge, D. R.

AU - Dispenzieri, Angela

AU - Murray, D. L.

PY - 2017/8/25

Y1 - 2017/8/25

N2 - We assessed the ability of a mass spectrometry-based technique, called monoclonal immunoglobulin rapid accurate mass measurement (miRAMM), to extend the analytical range of M-protein detection in serum samples obtained from myeloma patients in stringent complete response (sCR) post-autologous stem cell transplant (ASCT). To aid the M-protein detection post ASCT, the accurate molecular mass of the M-protein light chain at diagnosis was determined in all patients (N=30) and used to positively identify clones in the sCR serum. Day 100 post-ASCT, sCR samples had miRAMM identifiable M-proteins in 81% of patients. Patients who had achieved only a partial remission (PR) pre-ASCT and those with IgG isotypes serum samples had the highest rate of M-protein detection by miRAMM. miRAMM positivity at single time points (day 100, 6 months or 12 months) did not correlate with progression-free survival (PFS). In contrast, sCR patients who did not decrease their miRAMM M-protein intensities in serial measurements had shorter PFS than those whose miRAMM intensities decreased (median 17.9 months vs 51.6 months; P<0.0017). miRAMM M-protein is a more sensitive blood-based test than traditional M-protein tests and could cost effectively aid in serially monitoring complete remission for continue response or biochemical relapse.

AB - We assessed the ability of a mass spectrometry-based technique, called monoclonal immunoglobulin rapid accurate mass measurement (miRAMM), to extend the analytical range of M-protein detection in serum samples obtained from myeloma patients in stringent complete response (sCR) post-autologous stem cell transplant (ASCT). To aid the M-protein detection post ASCT, the accurate molecular mass of the M-protein light chain at diagnosis was determined in all patients (N=30) and used to positively identify clones in the sCR serum. Day 100 post-ASCT, sCR samples had miRAMM identifiable M-proteins in 81% of patients. Patients who had achieved only a partial remission (PR) pre-ASCT and those with IgG isotypes serum samples had the highest rate of M-protein detection by miRAMM. miRAMM positivity at single time points (day 100, 6 months or 12 months) did not correlate with progression-free survival (PFS). In contrast, sCR patients who did not decrease their miRAMM M-protein intensities in serial measurements had shorter PFS than those whose miRAMM intensities decreased (median 17.9 months vs 51.6 months; P<0.0017). miRAMM M-protein is a more sensitive blood-based test than traditional M-protein tests and could cost effectively aid in serially monitoring complete remission for continue response or biochemical relapse.

UR - http://www.scopus.com/inward/record.url?scp=85028453373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028453373&partnerID=8YFLogxK

U2 - 10.1038/bcj.2017.75

DO - 10.1038/bcj.2017.75

M3 - Article

C2 - 28841203

AN - SCOPUS:85028453373

VL - 7

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 8

M1 - e590

ER -